John Wood joined Tocagen in January 2016 as vice president of regulatory affairs and quality assurance. John holds more than 20 years of regulatory affairs experience focusing on first-in-class drugs for diseases with high unmet need. Previously, while at IDEC Pharmaceuticals, John played a leading role, in close collaboration with Genentech, in the first regulatory approval of RITUXAN® for the treatment of immune system B-cell malignancies. Prior to joining Tocagen, John headed regulatory affairs at Arena Pharmaceuticals where he played an integral role interfacing with Eisai, Inc. regarding regulatory strategy for life cycle management of BELVIQ®. Previous to this role Mr. Wood headed regulatory affairs and alliance management at Amylin Pharmaceuticals, Inc., where he directed activities surrounding the first regulatory approvals of SYMLIN® and BYETTA® in the U.S. and served as program leader for BYETTA and the primary interface with Eli Lilly. Prior to Amylin Pharmaceuticals, Inc., Mr. Wood held regulatory leadership positions at Quintiles Consulting and Gensia, Inc. Mr. Wood holds a bachelor’s degree in biology from University of California, San Diego, and is Regulatory Affairs Certified by the Regulatory Affairs Professionals Society (RAPS).